Frontlight ResearchEarly access
CompletedPhase 2
Beta-glucan and Immune Response to Influenza Vaccine
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 78 people enrolled
- Started
- 18 Jul 2022
- Ended
- 28 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Influenza Vaccine
- Beta-glucan
- Placebo
- Record updated
- 6 November 2025
Who can take part
- Age
- 50 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult volunteers ≥ 50 years of age
- Planning to be vaccinated for influenza
- Have been immunized for COVID-19
- Willing and able to provide written informed consent in English
- Willing and able to comply with all the study-related procedures, including attending to study visits for blood draw, taking the influenza vaccine, intake of the study supplement, and completing study questionnaires
Who cannot take part
- Have an immune system alteration because of an underlying illness (e.g., autoimmune disease) or immune-suppressing treatment (e.g., steroids (last 30 days); cytotoxic drugs, medical surgery, or radiation therapy during the 6 months, previous to enrollment)
- Have a history of a severe reaction or hypersensitivity following vaccination with influenza vaccine, vaccination with any other vaccine containing the same substances, or intake of the study product
- Demonstrate an inability to comply with the study-related procedures
- Be concurrently participating in a clinical trial that, in the judgement of the investigator, would interfere with the evaluation of the study outcomes
Where in United States
- Food Science and Human Nutrition Department, University of FloridaGainesville, United States
About the trial
What the trial wants to find out
This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.
The 2 groups in the trial
- Beta-glucanTreatment being tested
500 mg/day beta-glucan
Treatment: Influenza Vaccine and Beta-glucan
- PlaceboPlacebo, for comparison
500 mg/day cellulose
Treatment: Influenza Vaccine and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Yeast-derived Beta-glucan Supplementation on Antibody Response Following Influenza Vaccination: A Randomized, Placebo-controlled Study (M-Unity)
- Publications
- Yeast Beta-Glucan Enhances Antibody Response Following Influenza Vaccination - A Double-Blind, Randomized, Placebo-Controlled Pilot Trial.Journal of dietary supplements, 2025
- Record updated
- 6 November 2025